SGLT-2 Inhibitors vs. Older Oral Agents as Second-Line Treatment for Type 2 Diabetes

SGLT-2 inhibitors appeared to be more effective than sulfonylureas and DPP-4 inhibitors in an observational study.

Evidence to guide choices among the growing array of possible second-line treatments for patients with type 2 diabetes (who have inadequate control with metformin) remains limited. Most trials of available agents have been placebo-controlled, with few direct comparisons among available drug classes. Notably, researchers in the GRADE trial compared four second-line options directly but did not include sodium-glucose cotransporter-2 (SGLT-2) inhibitors (NEJM JW Gen Med Oct 15 2022 and N Engl J Med 2022; 387:1063, 1075).

Researchers emulated a pragmatic randomized trial by using British national databases that contained information on 75,000 patients (mean age, 60) with diabetes who added SGLT-2 inhibitors, sulfonylureas, or dipeptidyl peptidas…

Reviewing Author

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

Bruce Soloway, MD

Disclosures

Editorial BoardsNew RoAR News (http://www.newroarnews.org)

SGLT-2 Inhibitors vs. Older Oral Agents as Second-Line Treatment for Type 2 Diabetes

Topics

Reviewing Author